Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg
of Arikayce™ versus placebo and daily dosing of 70 mg and 140 mg of Arikayce™ versus placebo
in patients who have Cystic fibrosis (CF) and chronic infection due to pseudomonas
aeruginosa.